The report covers forecast and analysis for the cancer drugs market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the cancer drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer drugs market on a global level.

In order to give the users of this report a comprehensive view on the cancer drugs market, we have include competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Therapy segments and cancer type segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions  mergers, new Therapy launch, agreements, partnerships, collaborations  joint ventures, research development, Therapy and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, Therapy portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region.

The study provides a decisive view on the cancer drugs market by segmenting the market based on therapy, cancer type, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on therapy the market is segmented into immunotherapy, targeted therapy, chemotherapy, hormone therapy and others. Key cancer type covered under this study includes breast cancer, blood cancer, gastrointestinal cancer, prostate cancer, skin cancer, lung cancer and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East  Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for cancer drugs based on individual therapy and cancer in all the regions and countries.

The report also includes detailed profiles of end players such as Bayer, GlaxoSmithKline, Novartis, Sanofi and Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Johnson and Johnson and Teva Pharmaceuticals among others.

This report segments the global cancer drugs market as follows:

Global Cancer Drugs Market: Therapy Segment Analysis
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others

Global Cancer Drugs Market: Cancer Type Segment Analysis.
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others

Global Cancer Drugs Market: Regional Segment Analysis

North America
U.S.

Europe
UK
France
Germany

Asia Pacific
China
Japan
India

Latin America
Brazil

Middle East and Africa